Can Vimseltinib Cause Liver Elevations?
No, vimseltinib does not cause clinically significant liver elevations or drug-induced liver injury (DILI). Multiple clinical trials and FDA approval data consistently demonstrate an absence of cholestatic hepatotoxicity or DILI with this agent 1, 2, 3.
Evidence from Clinical Trials
The safety profile of vimseltinib across multiple studies is remarkably clean regarding hepatotoxicity:
Phase 3 MOTION trial: No evidence of cholestatic hepatotoxicity or drug-induced liver injury was noted among 83 patients treated with vimseltinib 1
Phase 1 study: Explicitly stated "no evidence of cholestatic hepatotoxicity or drug-induced liver injury" in 69 patients (37 with solid tumors, 32 with TGCT) 2
Phase 2 expansion cohort: Again confirmed absence of cholestatic hepatotoxicity or DILI in 66 patients across two cohorts 3
Safety Profile Context
The majority of treatment-emergent adverse events with vimseltinib were grade 1 or 2 1. The only grade 3 or 4 adverse event occurring in >5% of patients was elevated creatine phosphokinase (10%), not liver enzymes 1.
This hepatic safety profile is particularly notable because:
Vimseltinib is a selective CSF1R inhibitor designed with switch-control specificity to avoid off-target kinase inhibition that might contribute to hepatotoxicity 4
Other agents in this class (like pexidartinib, another CSF1R inhibitor) have been associated with severe hepatotoxicity including liver failure, making vimseltinib's clean liver profile a distinguishing advantage 5
Clinical Monitoring Implications
While vimseltinib does not cause liver elevations, standard oncology practice would still include baseline and periodic liver function monitoring as part of comprehensive safety assessment. However, you should not expect or anticipate hepatotoxicity with this agent based on current evidence.
The FDA label data provided appears to reference VIMPAT (lacosamide, an antiepileptic), not vimseltinib, which is a documentation error in the source materials 6. The actual vimseltinib clinical data consistently shows no hepatotoxic signal.